Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TMC Likes Its Options: Hospital Marketer Gains Rights To ProFibrix

This article was originally published in The Pink Sheet Daily

Executive Summary

The Medicines Company agreed to pay $10 million upfront to ProFibrix for an option to acquire the company outright after Phase III data on the lead biologic, Fibrocaps, read out later this year.

You may also be interested in...



The Medicines Co. Enters PCSK9 Race With Alnylam Deal

The Medicines Company and RNAi therapeutics company Alnylam have teamed up to develop a new drug targeting PCSK9 for the treatment of high cholesterol, but they are far behind the leaders in the pack and will have to differentiate their product from the others in the race.

Everyone Wins In Deal Between BMS And The Medicines Co.

Bristol-Myers Squibb has agreed to license its already-marketed topical hemostat to The Medicines Company for $115 million upfront and royalties. The agreement will last for two years and add to The Medicines Co.'s portfolio of perioperative care products.

Farxiga CKD Trial Stopped Early For Efficacy, Giving The SGLT2 Inhibitor An Edge

A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS075915

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel